NOTES TO EDITORS

About CKD

Chronic kidney disease (CKD) affects more than 200 million people worldwide and more than 30 million adults in the U.S. Although it can occur at any age, it becomes more common in aging populations and the prevalence is increasing. Anemia is a common complication of CKD and is associated with significant morbidity and mortality in dialysis and non-dialysis populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need. Currently, no curative treatment or ability to stop kidney deterioration in patients with CKD exists with the exception of kidney transplantation.

About the University of Michigan

The University of Michigan Health System creates the future of health care through medical education, patient care and research. UMHS is a community of more than 26,000 faculty, staff, trainees and volunteers, including 3 hospitals and 40 outpatient locations. The University of Michigan Medical School consistently ranks among the top research universities in the United States and world. With one of the nation's largest research budgets, The University of Michigan finds new ways to understand, diagnose, treat, manage and prevent many human diseases.

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centers, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:www.astrazeneca.com

AstraZeneca plc issued this content on 11 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 February 2016 12:09:26 UTC

Original Document: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/AstraZeneca-and-Medimmune-enter-consortium-to-deliver-new-treatments-for-chronic-kidney-disease-11022016.html